Royds Withy King advise Oxford Genetics on £7.5million investment
PUBLISHED: 12:45 29 November 2017 | UPDATED: 12:45 29 November 2017
Richard Cave Photography
Corporate lawyers law firm Royds Withy King in Oxford have advised Oxford Genetics, a leader in innovative synthetic biology-based technologies, on a £7.5 million investment into its operations in the US and the UK
This investment agreement between Oxford Genetics and Mercia Technologies PLC, an existing investor, and new investors Invesco Perpetual will fund a new office in Boston, US and a 6,000-sq. ft. extension of its UK facility at the Oxford Science Park this month. The extension will include state-of-the-art cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems and process development facilities.
The company also plans to invest in its research and development capabilities to increase its intellectual property portfolio and support the growth of its of technology-enabled licensing business.
Jennifer Sampson, corporate lawyer at Royds Withy King, said, “We are delighted to have advised on the deal that will help our client to innovate in cell and gene therapy, fund a new office in Boston and extend its UK facilities. Oxfordshire is a hub for life sciences businesses. It has been a fantastic opportunity to facilitate a substantial investment into a highly innovative business and see sector growth in the region. We wish Ryan and his team all the best in their next phase of development.”
Commenting on the deal, Ryan Cawood, CEO of Oxford Genetics, added, “Working with Royds Withy King on this deal was great, they supported Oxford Genetics throughout and helped us negotiate this strategic investment that will allow us to significantly expand our operations. Having a lawyer who responded to emails at 6am in the morning of our closing was pretty reassuring! We certainly look forward to working with Jennifer and the team again.”